After having corrected for these apparent mistakes , we conducted a sensitivity analysis in which we also accounted for a possible moderating effect of age ; while this suggests SSRIs to be safe drugs in the non-elderly , they do confirm what is already known , that is , that they may enhance the risk for SAEs in the old .
According to a systematic review on the use of selective serotonin reuptake inhibitors ( SSRIs ) in adult depression that was recently published in BMC Psychiatry , the results of which have been widely disseminated in lay media , these drugs increase the risk for serious adverse events ( SAEs ) while exerting poor antidepressant efficacy .
A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.
Paroxetine is a novel antidepressant that selectively inhibits neuronal reuptake of serotonin . Results are reported from a 6-week , double-blind trial of paroxetine , imipramine , and placebo in 120 out patients with DSM-III major depression .  Paroxetine was significantly superior to placebo on almost all measures . This included the main outcome variable , the Hamilton Rating Scale for Depression ( HAM-D ) , and its factor scores , anxiety-somatization , cognitive disturbance , psychomotor retardation , and sleep disturbance . There were no significant differences between paroxetine and imipramine on the same scales . Imipramine-treated patients were significantly more likely than those taking placebo to report one or more adverse effects , which were predominantly anticholinergic in nature . There was no significant difference in the number of paroxetine and placebo patients who reported one or more adverse effects . The results of this and similar studies indicate that paroxetine is an effective treatment in major depression and has a favorable side effect profile
After having corrected for these apparent mistakes , we conducted a sensitivity analysis in which we also accounted for a possible moderating effect of age ; while this suggests SSRIs to be safe drugs in the non-elderly , they do confirm what is already known , that is , that they may enhance the risk for SAEs in the old .
According to a systematic review on the use of selective serotonin reuptake inhibitors ( SSRIs ) in adult depression that was recently published in BMC Psychiatry , the results of which have been widely disseminated in lay media , these drugs increase the risk for serious adverse events ( SAEs ) while exerting poor antidepressant efficacy .